📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 16:52
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
14 announcements match the current filters (relevance ≥ 5).
20% YoY Revenue Growth in Q1 FY27; Anti-Dumping Duty Approved for Key Products
NOCIL reported a strong Q1 FY27 with revenue reaching Rs 403 crore, a 20% YoY increase driven by 9% volume growth and higher realizations. EBITDA margins expanded to 11.2%, leading to a 61% YoY growth in PAT to Rs 28 crore. A significant regulatory tailwind was confirmed with the approval of anti-dumping duties on Sulphonamides and a positive recommendation for Pilflex 13, covering 25-30% of the company's top line. Management has provided a robust revenue guidance of Rs 1,400 to Rs 1,600 crore for FY27 with EBITDA margins around 10%.
Confidence: HIGH
What changedNOCIL has transitioned from a period of intense pricing pressure to a recovery phase, supported by volume growth and favorable regulatory protection against imports.
Why it mattersAs India's largest rubber chemicals manufacturer with a 40% domestic market share, the implementation of anti-dumping duties provides a critical margin floor against cheap imports, especially as the company targets a higher export mix of 40-45%.
Q1 FY27 Revenue: Rs 403 crYoY Revenue Growth: 20%EBITDA Margin: 11.2%FY27 Revenue Guidance: Rs 1,400 - 1,600 crNew Capex vs Market Cap: ~4.7%
📅 Short termThe stock may react positively to the strong earnings recovery and the clarity provided on anti-dumping duty implementations which protect a third of their portfolio.
📈 Long termStructural growth is expected from the 'China+1' strategy, increasing specialty chemical contribution to 20-25%, and expanding global market share through exports.
⚠ Risk flags
- High dependence on the tyre industry (67% of revenue)
- Vulnerability to crude-linked raw material price volatility
- Potential for foreign competitors to absorb anti-dumping duties
Key Highlights
Revenue grew 20% YoY to Rs 403 crore in Q1 FY27, with a 22% sequential increase.
EBITDA increased 48% YoY to Rs 45 crore, with margins expanding 210 bps to 11.2%.
Anti-dumping duty on Sulphonamides (CBS and NS) was approved on June 20, 2026.
Management guided for FY27 revenue of Rs 1,400-1,600 crore, significantly higher than the TTM revenue of Rs 652 crore.
New Rs 130 crore investment in Dahej is progressing despite geopolitical disruptions.
👀 What to Watch
Watch for the formal government notification of anti-dumping duties on Pilflex 13 and the commercial ramp-up of the new TDQ plant in Dahej to validate the FY27 revenue guidance.
61% Profit Growth in Q1 FY27; NOCIL Announces New ₹130 Cr Capex at Dahej
NOCIL reported a strong Q1 FY27 with revenue growing 20% YoY to ₹403 crore and net profit surging 61% to ₹28 crore. The performance was bolstered by a 9% volume growth and EBITDA margin expansion of 210 bps to 11.2%, driven by operating efficiencies and inventory gains. Significantly, the company announced a fresh ₹130 crore brownfield capex at its Dahej facility for peak-utilization products, which is in addition to an ongoing ₹250 crore project. This total capex commitment of ₹380 crore represents approximately 58% of FY26 revenue, signaling aggressive growth intent.
Confidence: HIGH
What changedNOCIL has moved from a period of subdued margins to a sharp recovery in profitability while simultaneously increasing its capital expenditure commitment for capacity expansion.
Why it mattersAs India's largest rubber chemicals manufacturer with a 40% market share, NOCIL's aggressive expansion (totaling ₹380 crore) positions it to capture 'China+1' export opportunities and growing domestic tyre demand.
Q1 FY27 Revenue: ₹403 croreQ1 FY27 Net Profit: ₹28 croreNew Capex Announcement: ₹130 croreTotal Capex vs FY26 Revenue: ~58.2%EBITDA Margin: 11.2%Volume Growth: 9% YoY
📅 Short termThe stock is likely to react positively to the significant earnings beat and the announcement of further capacity expansion, reflecting management confidence.
📈 Long termThe combined ₹380 crore investment in Dahej is structurally significant, potentially re-rating the company as it scales capacity and improves backward integration by H1 FY28.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High client concentration with 67% revenue from the tyre industry
- Vulnerability to crude-linked raw material price fluctuations
- Potential pricing pressure from Chinese and EU imports
Key Highlights
Revenue from operations increased 20% YoY to ₹403 crore for the quarter ended June 30, 2026
Net profit grew 61% YoY to ₹28 crore, with EBITDA margins expanding to 11.2%
Announced a new ₹130 crore brownfield expansion at Dahej, targeted for completion by H1 FY28
Ongoing ₹250 crore capex at Dahej has moved into the trial production phase
Sales volumes grew 9% YoY, supported by strong domestic demand following GST 2.0 implementation
👀 What to Watch
Monitor the ramp-up of the ₹250 crore project currently in trial production and the execution timeline of the newly announced ₹130 crore expansion. Investors should also track the sustainability of the 11.2% EBITDA margin against volatile crude-linked raw material costs.
20% Revenue Growth in Q1 FY27; EBITDA Margins Expand to 11.2%
NOCIL reported a strong Q1 FY27 with revenue reaching ₹403 cr, a 20% YoY increase driven by 9% volume growth. Operating EBITDA grew 48% YoY to ₹45 cr, with margins expanding 210 bps to 11.2% due to higher average selling prices and volume gains. Net profit rose 61% YoY to ₹28 cr. The company is progressing on its TDQ facility expansion in Dahej, with Capital Work-in-Progress (CWIP) standing at ₹221 cr as of March 2026.
Confidence: HIGH
What changedNOCIL transitioned from a period of margin pressure (8.8% TTM OPM) to a stronger 11.2% margin in Q1 FY27, alongside significant revenue growth.
Why it mattersThe recovery in margins and double-digit domestic volume growth suggest improved demand from the tyre industry (67% of revenue) and successful price pass-throughs of raw material costs.
Q1 FY27 Revenue: ₹403 crQ1 Revenue vs TTM Revenue: 61.8%EBITDA Margin: 11.2%Net Profit Growth (YoY): 61%CWIP as of March 2026: ₹221 cr
📅 Short termPositive sentiment is expected due to the sharp recovery in profitability and margins compared to previous quarters, despite a 3% QoQ volume dip due to utility constraints.
📈 Long termStructural growth depends on the 'China+1' strategy and the successful ramp-up of the ₹250 cr TDQ expansion to diversify the product basket and increase export share.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependence on the tyre industry (67% revenue)
- Vulnerability to raw material price spikes
- Supply-side utility constraints and logistical challenges
Key Highlights
Net Revenue from Operations increased 20% YoY to ₹403 cr in Q1 FY27
Operating EBITDA margin expanded by 210 basis points YoY to 11.2%
Net Profit grew 61% YoY to ₹28 cr, compared to ₹17 cr in Q1 FY26
Volume growth of 9% YoY, with domestic volumes seeing double-digit growth
Capital Work-in-Progress (CWIP) reached ₹221 cr as of March 2026, primarily for the TDQ facility
👀 What to Watch
Monitor the commissioning timeline of the new TDQ facility in Dahej and the sustainability of the 11.2% EBITDA margin amidst volatile raw material prices and logistical challenges.
NOCIL Approves Q1 FY27 Results; Consolidated Performance Includes PIL Chemicals
NOCIL Limited's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in a meeting held on August 3, 2026. The consolidated results incorporate the performance of its wholly-owned subsidiary, PIL Chemicals Limited. While specific Q1 revenue and profit figures were not detailed in the provided text, the company continues to operate as a single-segment entity focused on rubber chemicals. Investors should evaluate these results against the TTM revenue of Rs 652.06 Cr and the historical operating margin of 8.8%.
Confidence: MEDIUM
What changedThe company has formally reported its financial performance for the first quarter of the 2026-27 fiscal year.
Why it mattersAs India's largest rubber chemicals manufacturer with a 40% domestic market share, NOCIL's quarterly performance is a key indicator of health in the domestic tyre industry, which accounts for 67% of its revenue.
Quarter Ended: June 30, 2026TTM Revenue: Rs 652.06 CrTTM Operating Margin: 8.8%Promoter Holding (Jun 2026): 33.76%Market Capitalization: Rs 2899 Cr
📅 Short termThe stock may see volatility as the market digests the specific Q1 growth figures relative to the Jun 2025 revenue of Rs 336.22 Cr.
📈 Long termStructural growth depends on the successful execution of the 'China+1' strategy and the ramp-up of value-added product capacities by H1 FY27.
⚠ Risk flags
- High client concentration (67% revenue from tyre industry)
- Pricing pressure from Chinese and EU imports
- Vulnerability to crude-linked raw material costs
Key Highlights
Board meeting held on August 3, 2026, lasting approximately 3 hours and 10 minutes (11:00 a.m. to 2:10 p.m.)
Approval of unaudited financial results for the first quarter ended June 30, 2026
Consolidation of wholly-owned subsidiary PIL Chemicals Limited confirmed under Ind AS 110
Company maintains a single reportable segment: Manufacture of Rubber Chemicals
TTM revenue as of the latest annual period stands at Rs 652.06 Cr with a PAT of Rs 26.51 Cr
👀 What to Watch
Investors should review the full P&L statement to check for margin recovery toward the 14-15% target and monitor the progress of the Rs 250 Cr TDQ capacity expansion in Dahej scheduled for H1 FY27.
NOCIL Announces ₹1.50 Dividend; Sets Record Date for July 24, 2026
NOCIL Limited has recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026. The company has fixed July 24, 2026, as the record date to determine shareholder eligibility for the payout. The dividend is subject to approval at the 64th Annual General Meeting scheduled for August 3, 2026, with payments starting on or after August 10, 2026. The announcement also provides detailed tax deduction (TDS) guidelines for various categories of resident and non-resident shareholders.
Key Highlights
Recommended a final dividend of ₹1.50 per equity share of ₹10 face value for FY 2025-26.
The record date for determining dividend eligibility is set for July 24, 2026.
Dividend payment will commence on or after August 10, 2026, following AGM approval.
Standard TDS of 10% applies to resident shareholders with valid PAN; 20% for those without.
Deadline for submitting tax exemption documents (Form 15G/H) is July 20, 2026.
👀 What to Watch
Investors should ensure their PAN and Aadhaar are linked and updated with their DP or RTA by July 20, 2026, to avoid a higher TDS rate of 20%. To be eligible for the ₹1.50 dividend, shares must be held in the portfolio as of the record date, July 24, 2026.
NOCIL Q4 FY26: Revenue Up 5% QoQ to ₹330 Cr; Volumes Reach 4-Year High
NOCIL reported a sequential revenue growth of 5% to ₹330 crores in Q4 FY26, supported by a 7% increase in volumes. While full-year FY26 revenue declined to ₹1,303 crores from ₹1,393 crores, the company saw a strong volume recovery in the second half with 12% growth. EBITDA margins for the quarter were pressured at 6.4% due to higher utility costs and dumping of low-priced imports, though management has initiated price hikes to offset rising raw material costs. Positive regulatory developments include DGTR's recommendation for anti-dumping duties on key products like TDQ and Sulphenamides.
Key Highlights
Q4 FY26 revenue stood at ₹330 crores with a 7% sequential volume growth, reaching levels not seen in 12 quarters.
Full-year FY26 volumes grew by 3%, driven by a significant 12% volume uptick in H2 FY26 compared to a 5% degrowth in H1.
DGTR recommended anti-dumping duties for antioxidant TDQ and Sulphenamides (CBS and NS) in March 2026, pending government approval.
Completed TDQ capex of under ₹250 crores at Dahej and announced a new ₹130 crore specialty rubber chemicals project for H1 FY28.
Operating EBITDA for Q4 stood at ₹21 crores with margins at 6.4%, impacted by higher gas prices and maintenance shutdowns.
👀 What to Watch
Investors should monitor the final notification of anti-dumping duties which could significantly improve realizations. While volume growth is robust, the focus remains on whether price hikes can successfully restore EBITDA margins to the 10-12% range.
NOCIL Sets July 24, 2026, as Record Date for Dividend Payment
NOCIL Limited has announced July 24, 2026, as the record date to determine eligibility for its upcoming dividend. The 64th Annual General Meeting (AGM) is scheduled for August 3, 2026, where the dividend proposal will be put to a shareholder vote. If approved, the dividend will be disbursed to eligible shareholders starting August 10, 2026. This is a routine corporate action following the Board's earlier recommendation of the dividend payout.
Key Highlights
Record date for dividend eligibility fixed as Friday, July 24, 2026
64th Annual General Meeting scheduled for August 3, 2026, at 3:00 PM IST
Dividend payment to commence on or after August 10, 2026, pending shareholder approval
Applicable to all beneficial owners in demat and physical forms as of the record date
👀 What to Watch
Investors looking to receive the dividend should ensure they hold the stock before the ex-dividend date. Existing shareholders should monitor the AGM results for final approval of the payout.
NOCIL Appoints Sanjiv Lal & Sabyaschi Patnaik as IDs; Re-appoints H.A. Mafatlal as Chairman
NOCIL Limited has announced a significant board restructuring, appointing two seasoned industry veterans, Mr. Sanjiv Lal and Mr. Sabyaschi Patnaik, as Independent Directors for five-year terms starting May 7, 2026. Mr. Lal brings 41 years of experience, including a tenure as CEO of Rallis India, while Mr. Patnaik offers over 30 years of expertise in the chemical sector. Furthermore, the company has re-appointed Mr. Hrishikesh A. Mafatlal as Executive Chairman for a five-year term beginning August 19, 2026. These appointments coincide with the conclusion of Mr. Vilas R. Gupte's tenure as an Independent Director on May 26, 2026.
Key Highlights
Appointment of Mr. Sanjiv Lal (ex-MD & CEO of Rallis India) as Independent Director for a 5-year term until May 2031
Appointment of Mr. Sabyaschi Patnaik (30+ years chemical sector experience) as Independent Director for a 5-year term
Re-appointment of Mr. Hrishikesh A. Mafatlal as Executive Chairman for a 5-year term starting August 19, 2026
Cessation of Mr. Vilas R. Gupte as Independent Director effective May 26, 2026, following completion of his term
👀 What to Watch
The induction of high-caliber professionals with deep chemical industry and leadership experience is a positive signal for corporate governance and strategic direction. Investors should view these appointments as a strengthening of the company's long-term management stability.
NOCIL Reports FY26 Revenue of ₹1,303 Cr; PAT Down 46% YoY Amid Pricing Pressure
NOCIL Limited reported a challenging FY26 with a 46% decline in Net Profit to ₹56 crore, primarily due to dumping pressure and pricing headwinds in the domestic market. Despite a 6% dip in annual revenue to ₹1,303 crore, the company achieved a 3% overall volume growth, driven by a strong 12% recovery in the second half of the year. The Dahej brownfield expansion involving a ₹250 crore capex has entered the trial production phase, signaling future capacity growth. Management successfully reduced working capital by streamlining inventory, leading to a significant improvement in cash flow from operations to ₹252 crore.
Key Highlights
FY26 Net Profit fell 46% YoY to ₹56 crore, while Revenue declined 6% to ₹1,303 crore
Achieved 3% volume growth for FY26, supported by a robust 12% volume surge in H2FY26
Operating EBITDA margins contracted to 7.7% in FY26 from 9.9% in the previous year
Dahej expansion project (₹250 crore) has commenced trial production and customer sampling
Inventory levels significantly reduced to ₹158 crore from ₹281 crore, optimizing working capital
👀 What to Watch
Investors should monitor the stabilization of margins as the company navigates dumping pressures and the ramp-up of the new Dahej capacity. While volume recovery is a positive lead indicator, the impact of international pricing competition remains a key risk.
NOCIL Commences Trial Batches for Rs 250 Crore Capacity Expansion at Dahej
NOCIL Limited has announced the commencement of trial batches for its rubber chemicals capacity expansion project at the Dahej plant. This project involves a capital expenditure not exceeding Rs 250 crore, as per the initial plan disclosed in March 2024. Following the trial runs, the company will send product samples to customers for quality approval. Commercial production will be announced separately once these approvals are secured, marking a key step in increasing the company's production capacity.
Key Highlights
Commencement of trial batches for rubber chemicals capacity enhancement at the Dahej facility.
Total capital expenditure for the expansion project is estimated at a maximum of Rs 250 crore.
Samples from trial runs to be sent to customers for necessary quality approvals.
Follow-up to the initial investment announcement made on March 26, 2024.
👀 What to Watch
Investors should monitor for the announcement of commercial production, which will signal the start of revenue generation from this new capacity. This expansion is a positive indicator of the company's long-term growth and market share aspirations in the rubber chemicals industry.
NOCIL to Invest INR 130 Crore for Capacity Expansion at Dahej Plant
NOCIL Limited has approved a capital expenditure of approximately INR 130 crores for a brownfield expansion at its Dahej plant in Gujarat. The project focuses on specialty rubber chemicals and includes backward integration of inputs to improve operational efficiencies. Currently, the company operates at 70% utilization of its 115,000 MTA capacity. The expansion is targeted for completion by H1 FY 2027-28 and will be funded primarily through internal accruals.
Key Highlights
Approved INR 130 crore investment for capacity expansion at the Dahej facility.
Project includes backward integration for specialty rubber chemicals to enhance margins.
Targeted completion date set for the first half of financial year 2027-28.
Funding to be managed largely through internal accruals, indicating a strong balance sheet.
Existing capacity stands at 115,000 MTA with current utilization around 70%.
👀 What to Watch
Investors should view this as a positive long-term growth signal that strengthens NOCIL's competitive position in specialty chemicals. Monitor the execution timeline and the ramp-up of utilization levels in the coming quarters.
NOCIL Q3 FY26: EBITDA Rises to Rs 27 Cr; Domestic Volumes Show High Single-Digit Growth
NOCIL reported Q3 FY26 revenue of Rs. 316 crores, a slight sequential decline from Rs. 321 crores due to pricing pressures and import dumping. Operating EBITDA improved to Rs. 27 crores (8.5% margin) from Rs. 22 crores in Q2, driven by domestic volume growth and cost-saving initiatives. The company expects to end FY26 with 3-4% volume growth, recovering from a 5% decline in the first half of the year. Management anticipates a recovery in US export volumes, which dropped 50% in Q3, within the next 2-3 months following tariff revisions.
Key Highlights
Q3 FY26 EBITDA increased to Rs. 27 crores from Rs. 22 crores in Q2, with margins at 8.5%
Domestic volumes grew in high single digits, while US export volumes fell by approximately 50% due to tariffs
Management guides for 3% to 4% overall volume growth for FY26 despite a 5% degrowth in H1
TDQ antioxidant capacity expansion at Dahej is ahead of schedule with trials starting in H1 CY2026
9-month PAT stood at Rs. 39 crores, significantly lower than Rs. 82 crores in the previous year
👀 What to Watch
Investors should monitor the outcome of anti-dumping investigations and the recovery of US export volumes. The upcoming TDQ capacity at Dahej provides a medium-term growth trigger.
NOCIL Q3FY26: Revenue at ₹316 Cr, EBITDA Margins Improve 140 bps QoQ to 8.5%
NOCIL reported a mixed Q3FY26 with revenue declining 1% QoQ to ₹316 crore, while Operating EBITDA grew 20% QoQ to ₹27 crore. Despite a 5% volume de-growth in H1FY26, the company expects full-year volume growth of 3-4% driven by high single-digit domestic demand recovery. Profitability remains under significant pressure with 9M Net Profit down 53% YoY to ₹39 crore due to persistent Chinese dumping and pricing challenges. However, the ₹250 crore Dahej brownfield expansion is progressing ahead of schedule, signaling long-term capacity readiness.
Key Highlights
Revenue for Q3FY26 stood at ₹316 crore, down 1% QoQ and 7% YoY from ₹340 crore.
Operating EBITDA margin improved by 140 bps QoQ to 8.5%, though 9M EBITDA remains 23% lower YoY.
Management maintains a full-year volume growth guidance of 3-4% despite a weak H1 performance.
₹250 crore Dahej expansion project is on track and expected to be completed ahead of schedule.
Net Profit for 9MFY26 fell 53% YoY to ₹39 crore, impacted by a ₹5 crore exceptional item related to new labour codes.
👀 What to Watch
Investors should monitor the sustainability of margin recovery and the impact of US tariffs on international volumes. The stock remains a long-term play on the 'China Plus One' strategy as the Dahej expansion nears completion.
NOCIL Board Approves Q3 FY26 Unaudited Standalone and Consolidated Financial Results
NOCIL Limited's Board of Directors met on February 11, 2026, to approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The consolidated results include the performance of its wholly-owned subsidiary, PIL Chemicals Limited. The statutory auditors, Kalyaniwalla & Mistry LLP, have completed their limited review and reported no material misstatements. The board meeting lasted approximately four and a half hours, concluding at 4:30 p.m. IST.
Key Highlights
Board approved Un-Audited Standalone and Consolidated Financial Results for the period ended December 31, 2025.
Consolidated results include the financial data of wholly-owned subsidiary PIL Chemicals Limited.
Statutory auditors issued a Limited Review Report with no qualifications or adverse findings.
The board meeting commenced at 12:00 Noon and concluded at 4:30 p.m. on February 11, 2026.
👀 What to Watch
Investors should review the detailed financial tables and management commentary once the full data is uploaded to the stock exchanges to assess margin performance and revenue growth.
